Q-omics provides the consensus-scored LALBA profile across patient tissues and cancer cell-line models. LALBA expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LALBA is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, LALBA RNA expression shows 6,466 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, KIRC, and STAD as cancer lineages where LALBA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LALBA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LALBA survival associations across molecular data types. LALBA RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LALBA RNA expression–survival associations across cancer types. High LALBA expression shows unfavorable associations in CHOL, KIRP, THYM, OV, ACC and UCS. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for LALBA RNA expression.
This table summarizes LALBA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LALBA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LALBA shows lower tumor expression in BRCA and higher tumor expression in KIRC, UCEC and LUSC. The KIRC box plot shows higher LALBA RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .003).
This table shows molecular features associated with LALBA in patient tissues and cancer cell lines. In patient samples, LALBA shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LALBA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
